Fig. 1 · Structure

Documents & Downloads

Theobromine (3,7-Dimethylxanthine)

Cat. No. A10925 CAS 83-67-0
Theobromine(3,7-Dimethylxanthine) is a xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than theophylline and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension.

In Stock

Publications for Theobromine

1 publication citing this product

  1. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

At 30 μM, theobromine increased basal synaptic transmission but reduced long-term potentiation in untreated mouse hippocampal slices. Adenosine removal, antagonists and knockout controls support A1-dependent basal facilitation and A2A-dependent modulation of plasticity. These functional results do not establish receptor-binding potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Theobromine (3,7-Dimethylxanthine) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Theobromine (3,7-Dimethylxanthine) from 2 published references.

Theobromine (3,7-Dimethylxanthine) In Vitro Studies

In primary mouse cortical neurons, 30 μM theobromine reduced apoptotic-like nuclear morphology during a 24 h, 500 nM Aβ1–42 challenge. The endpoint was DAPI morphology rather than a biochemical apoptosis assay. [1]

Adenosine-dependent synaptic effects in mouse hippocampal slices

Cell-based study · Acute hippocampal slices from 8–10-week-old C57BL/6J mice, plus global and forebrain-neuronal A2A receptor knockouts. [1]

Theobromine reversibly increased basal transmission but reduced LTP in untreated slices. Adenosine removal and receptor controls support A1-dependent basal facilitation and A2A-dependent LTP modulation. These are functional tissue effects, not direct receptor-binding potency measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal fEPSP slope change relative to pretreatment baselinemean ± SEM 34.04 ± 2.80%; p < 0.001 vs baseline (0%); n = 22[1]
LTP magnitude, control versus theobrominemean ± SEM 66.99 ± 10.29% vs 24.39 ± 7.03%; p < 0.01; n = 6[1]
Adenosine and receptor dependencequalitative ADA (2 U/mL) occluded basal facilitation and LTP reduction; DPCPX (100 nM) occluded basal facilitation but did not prevent LTP reduction; A2A deletion preserved basal facilitation but eliminated significant LTP reduction.[1]
LTP with SCH58261 alone versus SCH58261 plus theobrominemean ± SEM 13.31 ± 3.74% vs 51.22 ± 7.72%; p < 0.05; n = 3–6[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM theobromine
Exposure duration
Basal effects assessed at 25–30 min; LTP quantified 50–60 min after induction.
Method
Bath superfusion of acute hippocampal slices.
Vehicle
Fresh aqueous stock diluted into ACSF; residual DMSO from antagonists controlled.
Co-treatment
Separate mechanistic comparisons with ADA 2 U/mL, DPCPX 100 nM or SCH58261 50 nM.
Reported limits
Captions and Methods disagree on induction frequency; exact stimulation frequency is not adopted. Global-knockout LTP n differs between text and caption; no exact knockout counts/means adopted.
Methods and source locations

Compound reported in the paper: Theobromine; Compound label in the paper: theo

Isolated mouse tissue or cells; no clinical efficacy established.

Results 2.1–2.4; Figures 1–5; Methods 4.2–4.4, 4.7

Basal fEPSP slope change relative to pretreatment baseline: Extracellular Schaffer fiber–CA1 recording; average 25–30 min after application. — Results 2.1; Figure 1B,C; Methods 4.4, 4.7

LTP magnitude, control versus theobromine: fEPSP slope change 50–60 min after induction relative to pre-induction baseline; comparison in different slices from the same animal. — Results 2.1; Figure 1D,E; Methods 4.4, 4.7

Adenosine and receptor dependence: Modifier-alone, control and knockout comparisons. — Results 2.2–2.4; Figures 2, 3, 5

LTP with SCH58261 alone versus SCH58261 plus theobromine: A2A antagonist SCH58261 (50 nM); adding theobromine increased LTP relative to SCH58261 alone. — Results 2.4; Figure 4C,D

Reduced apoptotic-like morphology during amyloid challenge

Cell-based study · Primary cortical neurons from C57BL/6 E17.5 mouse embryos, treated on culture day 5. [1]

Theobromine reduced apoptotic-like DAPI nuclear morphology during Aβ1–42 exposure. Untreated, theobromine-alone and peptide-alone controls were included. Caffeine was a separate comparator, not a combination. This morphological endpoint does not establish clinical neuroprotection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptotic-like cells as percentage of total neurons: Aβ alone versus Aβ plus theobrominemean ± SEM 31.58 ± 4.25% vs 13.46 ± 3.52%; p < 0.05; n = 4[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM theobromine with 500 nM Aβ1–42
Exposure duration
24 h
Method
Addition to culture medium on day 5; drugs present during peptide challenge.
Vehicle
Theobromine stock in milliQ water, diluted in neuronal culture medium.
Co-treatment
Aβ1–42 challenge; caffeine 50 μM tested separately.
Reported limits
The selected experiment measures nuclear morphology, without an independent biochemical apoptosis endpoint.
Methods and source locations

Compound reported in the paper: Theobromine; Compound label in the paper: theo

Isolated mouse tissue or cells; no clinical efficacy established.

Results 2.5; Figure 6E,F; Methods 4.3, 4.5–4.7

Apoptotic-like cells as percentage of total neurons: Aβ alone versus Aβ plus theobromine: DAPI: condensed, irregular or fragmented nuclei; four fields per coverslip. Caption reports four experiments; Methods defines n as determinations from different mice. — Results 2.5; Figure 6E,F; Methods 4.5–4.7

Theobromine (3,7-Dimethylxanthine) In Vivo Studies

Male rats fed chow containing 0.05% (W/W) theobromine for 73 days made fewer working-memory errors and completed a radial-arm maze faster than controls. Reference-memory errors showed no significant group effect. Higher medial-prefrontal BDNF accompanied these findings, without a causal test. [2]

Dietary theobromine in a rat radial-arm-maze cohort

Animal study · Male Wistar rats, 5 weeks old at admission; Experiment 1, n = 12 per diet group. [2]

Theobromine diet was associated with fewer working-memory errors and shorter maze latency, without a significant group effect on reference-memory errors. Medial-prefrontal BDNF was higher in a subset. The BDNF association does not establish causality; food restriction limits generalization.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Working-memory errors across five blocks of five trialsANOVA Group F(1,88) = 27.265, p < 0.0001; block × group F(4,88) = 3.131, p < 0.05[2]
Reference-memory errorsgroup effect No significant main group effect or block × group interaction reported.[2]
Time to complete maze trialANOVA Group F(1,88) = 21.558, p < 0.0001; block × group F(4,88) = 2.815, p < 0.05[2]
Medial-prefrontal cortex BDNF proteinbetween-group comparison Higher in TB rats; p = 0.009; n = 5 per group[2]

Conditions shared by the study groups

Route
Oral dietary intake.
Frequency
Diet throughout experiment; food restriction during behavioral training.
Treatment course
Day 0 to day 73; Figure 1 shows preparation around day 35 and maze testing from day 42.
Vehicle
CRF-1 chow; supplemented chow attributed to Oriental Yeast Co. Ltd.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Theobromine-supplemented chow versus standard chow
0.05% (W/W) theobromine in CRF-1 chow; not a measured mg/kg dose.
CRF-1 chow without TB supplementation, with the same maze and food-restriction procedures.Fewer working-memory errors and shorter latency; no significant reference-memory group effect; higher medial-prefrontal BDNF in n = 5 subset.[2]
Theobromine-supplemented chow versus standard chow
Model: Male Wistar rats; Experiment 1; n = 12 per group.
Reported limits: Measured intake per kg and analytical purity/lot identity not established. Random assignment and blinded maze scoring not established in read Experiment 1 methods.
Methods and source locations

Compound reported in the paper: Theobromine; Compound label in the paper: TB

Male-rat dietary model; diet percentage is not measured daily intake.

Experiment 1: Methods 2.1–2.4, 2.7–2.8; Results 3.1; Figures 1, 3–4

Working-memory errors across five blocks of five trials: Repeated entries within a trial; mean ± SEM displayed; n = 12 per group. — Results 3.1.2; Figure 3A; Methods 2.2.1, 2.7–2.8

Reference-memory errors: Entries into unbaited arms; same cohort, n = 12 per group. — Results 3.1.2; Figure 3B; Discussion

Time to complete maze trial: Total time; five-trial blocks; n = 12 per group; no exact graph means inferred. — Results 3.1.2; Figure 3C

Medial-prefrontal cortex BDNF protein: ELISA normalized to protein; Figure 4 displays mean ± SEM; no exact bar heights extracted. — Results 3.1.3; Figure 4; Methods 2.4, 2.7–2.8

Theobromine-supplemented chow versus standard chow · Methods 2.1–2.2.1; Figure 1; Results 3.1; Figures 3–4

Specifications

Manufacturer Adooq Bioscience
CAS Number 83-67-0
Formula C7H8N4O2
Molecular Weight 180.2
Synonyms 3,7-Dimethylxanthine; Diurobromine; Santheose; Teobromin; Theosalvose; Theostene
SMILES
CN1C=NC2=C1C(=O)NC(=O)N2C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Theobromine (3,7-Dimethylxanthine) Research References

  1. [1] Valada P, Alçada-Morais S, Cunha RA, et al. Thebromine Targets Adenosine Receptors to Control Hippocampal Neuronal Function and Damage International journal of molecular sciences (2022). PMID: 36142422 DOI: 10.3390/ijms231810510 Source material
  2. [2] Islam R, Matsuzaki K, Sumiyoshi E, et al. Theobromine Improves Working Memory by Activating the CaMKII/CREB/BDNF Pathway in Rats Nutrients (2019). PMID: 31010016 DOI: 10.3390/nu11040888 Source material

Publications

1 publication citing this product

  1. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489

Added to your cart

View Cart Checkout
Loading...